Jiangxi Kerui Pharmaceutical Co. Ltd. has reported new sodium channel protein type 10 subunit α (SCN10A; Nav1.8) blockers reported to be useful for the treatment of acute pain.
Shenzhen Targetrx Inc. has patented proteolysis targeting chimeras (PROTACs) comprising cereblon ligands coupled to a hepatocyte growth factor receptor (HGFR, MET)-targeting moiety via linker acting as HGFR degradation inducers potentially useful for the treatment of cancer.
Shanghai Escugen Biotechnology Co. Ltd. has disclosed new antibody-drug conjugates comprising chimeric monoclonal antibodies targeting CD174 (Lewis y) covalently linked to a cytotoxic drug. They are potentially useful for the treatment of cancer.
Work at Chengdu Shibeikang Biological Medicine Technology Co. Ltd. has led to the identification of new gadolinium complexes reported to be potentially useful as magnetic resonance imaging (MRI) contrast agents.
Shijiazhuang Yiling Pharmaceutical Co. Ltd. has divulged new lysophosphatidic acid receptor 1 (LPAR1; EDG2) antagonists potentially useful for the treatment of pulmonary fibrosis.
Tikva Allocell Pte. Ltd. has closed an $8 million series A financing to support its development of engineered, allogeneic cell therapies for adult and pediatric patients with solid tumors.
Abera Bioscience AB has announced, together with clinical partner Radboud University Medical Center, the submission of a clinical trial application in the Netherlands to initiate a phase I trial of its serotype-independent pneumococcal vaccine candidate AB-01.12.
Outer membrane vesicles (OMVs), naturally released by gram-negative bacteria, are promising platforms for mucosal vaccines due to their immunostimulatory properties and ability to display antigens. Abera Bioscience AB previously developed an OMV platform using genetically engineered bacteria with covalent antigen decoration via Spycatcher/Tag technology.
Pancreatic polypeptide (PP) selectively activates NPY4 receptors, a signaling pathway that may become impaired as NPY levels decline during Alzheimer’s disease progression. Researchers from Henan University of Chinese Medicine described P1642-1, a novel PP analogue, in the 5×FAD mouse model of AD.
Evogene Ltd. and Eleo Inc. have established a strategic scientific collaboration to discover and develop next-generation oral small-molecule inhibitors targeting the PCSK9 pathway for the treatment of hyperlipidemia and cardiovascular diseases.
RSS
